EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?

被引：7
作者：
Sesbouee, R. [1 ]
Le Pessot, F. [2 ,3 ,4 ]
Di Fiore, F. [1 ,5 ]
Frebourg, T. [1 ,6 ]
机构：
[1] Univ Rouen, INSERM, Inst Biomed Res & Innovat, U614, F-76183 Rouen, France
[2] Univ Hosp, Lab Tumour Genet, F-76031 Rouen, France
[3] Univ Hosp, Dept Pathol, F-76031 Rouen, France
[4] Univ Hosp, Uro Digest Oncol Unit, Dept Gastroenterol, F-76031 Rouen, France
[5] Univ Hosp, Mol Genet Lab, F-76031 Rouen, France
[6] Univ Hosp, Dept Genet, F-76031 Rouen, France
来源：
BRITISH JOURNAL OF CANCER | 2012年 / 106卷 / 02期
关键词：
COLORECTAL-CANCER PATIENTS; GEFITINIB; PTEN;
D O I：
10.1038/bjc.2011.570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：426 / 427
页数：2
相关论文
共 8 条
[1]   EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer [J].
Algars, A. ;
Lintunen, M. ;
Carpen, O. ;
Ristamaki, R. ;
Sundstrom, J. .
BRITISH JOURNAL OF CANCER, 2011, 105 (02) :255-262
[2]   A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation [J].
Cascinu, S. ;
Berardi, R. ;
Salvagni, S. ;
Beretta, G. D. ;
Catalano, V. ;
Pucci, F. ;
Sobrero, A. ;
Tagliaferri, P. ;
Labianca, R. ;
Scartozzi, M. ;
Crocicchio, F. ;
Mari, E. ;
Ardizzoni, A. .
BRITISH JOURNAL OF CANCER, 2008, 98 (01) :71-76
[3]   MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Mitsudomi, Tetsuya ;
Song, Youngchul ;
Hyland, Courtney ;
Park, Joon Oh ;
Lindeman, Neal ;
Gale, Christopher-Michael ;
Zhao, Xiaojun ;
Christensen, James ;
Kosaka, Takayuki ;
Holmes, Alison J. ;
Rogers, Andrew M. ;
Cappuzzo, Federico ;
Mok, Tony ;
Lee, Charles ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
SCIENCE, 2007, 316 (5827) :1039-1043
[4]   PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients [J].
Frattini, M. ;
Saletti, P. ;
Romagnani, E. ;
Martin, V. ;
Molinari, F. ;
Ghisletta, M. ;
Camponovo, A. ;
Etienne, L. L. ;
Cavalli, F. ;
Mazzucchelli, L. .
BRITISH JOURNAL OF CANCER, 2007, 97 (08) :1139-1145
[5]   An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology [J].
Martin, V. ;
Mazzucchelli, L. ;
Frattini, M. .
JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (04) :314-324
[6]   Moderate amplifications of the c-myc gene correlate with molecular and clinicopathological parameters in colorectal cancer [J].
Masramon, L ;
Arribas, R ;
Tórtola, S ;
Perucho, M ;
Peinado, MA .
BRITISH JOURNAL OF CANCER, 1998, 77 (12) :2349-2356
[7]   Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study [J].
Moroni, M ;
Veronese, S ;
Benvenuti, S ;
Marrapese, G ;
Sartore-Bianchi, A ;
Di Nicolantonio, F ;
Gambacorta, M ;
Siena, S ;
Bardelli, A .
LANCET ONCOLOGY, 2005, 6 (05) :279-286
[8]   Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study [J].
Razis, Evangelia ;
Briasoulis, Evangelos ;
Vrettou, Eleni ;
Skarlos, Dimosthenis V. ;
Papamichael, Dimitrios ;
Kostopoulos, Ioannis ;
Samantas, Epaminontas ;
Xanthakis, Ioannis ;
Bobos, Mattheos ;
Galanidi, Eleni ;
Bai, Maria ;
Gikonti, Ioanna ;
Koukouma, Alona ;
Kafiri, Georgia ;
Papakostas, Pavlos ;
Kalogeras, Konstantine T. ;
Kosmidis, Paris ;
Fountzilas, George .
BMC CANCER, 2008, 8 (1)
1